Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021)
-
Published:2021-12-16
Issue:7
Volume:49
Page:485-495
-
ISSN:2587-9294
-
Container-title:Almanac of Clinical Medicine
-
language:
-
Short-container-title:Alʹm. klin. med.
Author:
Belousova E. A.1ORCID, Kozlov I. G.2, Abdulganieva D. I.3ORCID, Alexeeva O. P.4ORCID, Gubonina I. V.5ORCID, Lishchinskaya A. A.6ORCID, Tarasova L. V.7, Chashkova E. Yu.8ORCID, Shapina M. V.9ORCID, Shifrin O. S.10, Shchukina O. B.11
Affiliation:
1. Moscow Regional Research and Clinical Institute (MONIKI) 2. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology;
I.M. Sechenov First Moscow State Medical University 3. Kazan State Medical University 4. Privolzhsky Research Medical University;
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko 5. Military Medical Academy named after S.M. Kirov 6. The Loginov Moscow Clinical Scientific Center 7. I.N. Ulianov Chuvash State University;
Republican Clinical Hospital of Chuvashia 8. Irkutsk Scientific Centre of Surgery and Traumatology 9. National Medical Research Centre for Coloproctology named after A.N. Ryzhikh 10. I.M. Sechenov First Moscow State Medical University 11. Academician I.P. Pavlov First St. Petersburg State Medical University
Abstract
On May 22, 2021, the Expert Board met in St. Petersburg to discuss their position on immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases (IBD). The Expert Board aimed at discussion of current strategies, development of a consensus on determination of an adequate biological treatment sequence for IBD. The main topics of the agenda were the contribution of immune system to the pathophysiology of Crohn's disease, ulcerative colitis and their complications, efficacy of genetically engineered biological agents (GEBA) at various stages of IBD management. Participation of the leading Russian experts in IBD, as well as involvement of other specialties, made it possible to consider the topic by a multidisciplinary team, with an in-depth analysis of IBD pathophysiology, to better understand the course of the disease in some contradictory situation, for instance, when clinical remission is not associated with an endoscopically confirmed remission. One of the expected effects of this Expert Board meeting would be an improvement of GEBA administration in clinical practice, mostly due to the modification of clinical guidelines. This would ascertain and confirm the algorithms for GEBA administration for IBD, including the optimal treatment sequence depending on an agent’s mechanism of action and the patient profile. The clarification of the optimal GEBA sequence in the clinical guidelines could lead to more frequent GEBA administration in local medical clinics and institutions in the regions, where GEBA are used insufficiently due to little experience and absence of their precise positioning in the clinical guidelines.
Publisher
Moscow Regional Research and Clinical Institute (MONIKI)
Reference53 articles.
1. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857): 1909–1915. doi: 10.1016/S0140-6736(12)61084-8. 2. Baumgart DC. Conventional medical management of ulcerative colitis: Tacrolimus. In: Baumgart D, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer; 2012. pp. 487–494. doi: 10.1007/978-1-4614-0998-4_40. 3. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110(9): 1324–1338. doi: 10.1038/ajg.2015.233. 4. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107(12): 1770–1776. doi: 10.1038/ajg.2012.117. 5. Russian Gastroenterological Association, Russian Association of Coloproctology. Ulcerative Colitis. Clinical Guidelines. KP 193/1. 2020. 68 p. [Internet]. Available from: https://ibd-care.ru/wp-content/uploads/2021/05/yazvennyj-kolit-2020.pdf.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The role of selenium in the pathogenesis and therapy of inflammatory bowel diseases;HERALD of North-Western State Medical University named after I.I. Mechnikov;2024-07-03
|
|